
The new LabVantage Enterprise SaaS adds full configurability and custom interfacing capabilities.
The new LabVantage Enterprise SaaS adds full configurability and custom interfacing capabilities.
NewAge Industries has completed a plant expansion that added new cleanrooms to its headquarters in Southampton, Pa.
Gyros’ new titer kit identifies adeno-associated virus serotype 9 in vector-based cell and gene therapy manufacturing.
CuriRx’s CuriLytics platform is a mass spectrometry instrument that will support complex biotherapeutics development.
The research collaboration between AstraZeneca and VaxEquity aims to discover and develop self-amplifying RNA therapeutics.
CPC’s MicroCNX Series Connectors provide an alternative to tube welding at small tubing sizes.
The joint venture with OSTHUS will expand PharmaLex’s IT consulting and system integration expertise.
AGC Biologics is expanding manufacturing capacity at its Heidelberg, Germany, facility for plasmid DNA and messenger RNA.
Vector Laboratories has completed a $124 million cash buyout backed by Thompson Street Capital Partners and will begin an acquisition strategy to expand protein detection capabilities.
Ardena acquires Idifarma, adding spray drying technology and high potency capabilities.
AstraZeneca and the European Commission have reached an agreement that ends legal proceedings over the execution of the advance purchase agreement for the delivery of Vaxzevria.
Thermo Fisher Scientific plans to expand its Nashville, Tenn., site by establishing a dedicated single-use technology manufacturing facility at the site, doubling capacity.
The US government has granted Thermo Fisher Scientific a $192.5 million contract that the company will use to expand domestic manufacturing for pipette tips.
Element’s acquisition of Impact Analytical expands their life sciences footprint in North America.
Febles will oversee day-to-day aseptic manufacturing at Pharmaceutics International, Inc.
CDMO ten23 health aims to support companies developing injectable biopharmaceutical drugs.
Avantor plans to address rising global demand for biologics with their investment in hydration capabilities.
Quotient Sciences is investing £6.3 million ($8.68 million) into their drug substance manufacturing capabilities.
The University of Southern California and Amgen have teamed up to provide researchers access to two of Thermo Fisher Scientific’s cryo-EM instruments.
A new membrane staining kit, ExoBrite, launched by Biotium aims to enhance the detection of exosomes through flow cytometry.
BioAgilytix, a US-based contract research laboratory focused on large-molecule drug development, has agreed to purchase 360biolabs, an Australia-based contract research organization specializing in virology and immunology.
AGC Biologics has broken ground on a new multipurpose facility in Copenhagen, Denmark, that will increase capacity.
Todos Medical has completed validation of its cPass neutralizing antibody blood test to monitor COVID-19 immunity.
Lonza plans to establish drug product manufacturing capabilities at is site in Guangzhou, China, to produce clinical trial and commercial supply in the country.
Bristol Myers Squibb has exercised the option to in-license an immune-modulating drug candidate developed by Exscientia.
Corning’s new Ascent fixed bed reactor (FBR) system is an automated bioproduction platform designed to significantly improve yields and reduce bioproduction costs.
BlueAllele has been granted a US patent for its advanced gene-editing technology, PALIDON, which is compatible with existing gene editing nucleases and delivery systems.
Syngene’s additions include a new microbial facility and an expanded mammalian facility.
Biotage’s new facility in Cardiff, UK, will produce lipids using large-scale flash purification.
Rentschler Biopharma has broken ground nearby its Milford, Mass., site where it will build its new multi-product manufacturing facility for commercial production of complex molecules.